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OBJECTIVES: Three formulations of leuprolide, an established LH-RH agonist are
used in the management of advanced prostate cancer. In order to inform clinical
practice, the economic impact of the different formulations and dosing schedules
were evaluated for Austria, Belgium, Czech Republic, Hungary, Italy, Latvia, The
Netherlands, Poland and Portugal.METHODS:Database searches identified 10 clin-
ical trials of leuprolide 1-monthly (1M), 3-monthly (3M) and 6-monthly (6M) with
Atrigel®, requiring 6, 4 and 2 hospital treatment visits respectively. Due to reported
comparable efficacy, safety and adherence, cost-minimisation analysis was con-
ducted. Costs of the product, specialist consultations and diagnostics (converted to
2010 euros) were considered during up to 12 months follow-up. The perspective
was that of public payers. RESULTS: The review showed that with the use of leu-
prolide 1M, 3M and 6M the respective percentage of patients achieving testosterone
suppression of 50ng/dl was 93.3%, 98.3% and 97.3% (p0.05). However, 6M was
the least cost treatment option, with average total annual costs from 788€ (Poland)
to 1839€ (Portugal). The 3M option was 2.5% (Hungary) to 37.6% (Belgium) higher
than 6M cost; while 1M formulation had the highest cost: 15.6% and 151.6% more
than 6M for those countries, respectively. The 3M option was 11.2% to 45.3% less
expensive than 1M. The cost drivers were the frequency of visits for injection and
monitoring. The study showed that up to 50% additional visits could be funded
with the savings resulting from switching eligible patients from 1M and 3M to 6M.
Results were robust in one-way sensitivity analyses, as well as probabilistic sensi-
tivity analysis. CONCLUSIONS: Leuprolide acetate with Atrigel® 1M, 3M and 6M
formulations offer comparable efficacy and safety. However, driven by the fre-
quency of visits, the 6-monthly formulation offers the greatest cost-savings for
prostate cancer patients in the European countries studied.
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THE ADJUVANT TREATMENT OF STAGE 3 COLON CANCER (ACC): AN INDIRECT
COST-MINIMISATION AND POPULATION NET HEALTH BENEFIT ANALYSIS OF
CAPECITABINE  OXALIPLATIN (XELOX) VS. IV 5-FU  FA  OXALIPLATIN
(FOLFOX)
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OBJECTIVES: XELOX is the most utilised therapy for aCC in the UK. The aim of this
analysis was to assess and compare the population net health benefit (pNHB) of all
patients with aCC switching from the FOLFOX regimen to XELOX, from a UK Na-
tional Health Service (NHS) perspective. METHODS: An indirect comparison of the
NO16968 (XELOX) and MOSAIC (FOLFOX-4) trials was undertaken (where both reg-
imens were compared to i.v. 5-FU plus FA) showing XELOX to be non-inferior. A cost
minimisation approach was therefore taken. Drug costs were based on UK list
prices taken from the British National Formulary (BNF 61), and additional costs
such as administration costs, adverse event costs and pharmacy costs were taken
from NHS reference costs, the literature and previous technology appraisals. A
£20,000/QALY assumed displacement threshold was utilised to estimate the pNHB
provided. Uncertainty was explored via one-way sensitivity analyses. RESULTS:
Replacing FOLFOX-6 and FOLFOX-4 with XELOX saved £6490 and £9778 per patient
respectively, of which £2434 and £1534 came from drug acquisition costs. Over 60%
of the total savings were realised from reductions in the frequency of pharmacy use
and administration resource use. The savings realised from full implementation of
the XELOX regimen could be used by the NHS to generate more than 1000 QALYs
over the next 5 years. The costs of AEs were similar across all three regimens.
XELOX achieved savings of £3,400 per patient even when all parameters in the
sensitivity analysis were simultaneously set to the worse case scenarios.
CONCLUSIONS: XELOX has been demonstrated to be cost-effective and signifi-
cantly cost-saving versus FOLFOX-4 and FOLFOX-6 in aCC from an NHS perspec-
tive. Full conversion of all aCC patients to XELOX could offer the NHS substantial
financial savings and a significant pNHB of over 1000 QALYs over a 5 year period.
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OBJECTIVES: The objective was to compare the first-line therapy costs of
capecitabinecisplatin(XP) and 5-FUcisplatin (FP) in patients with AGC in the
Romanian health care system. METHODS: Due to similar efficacy as shown in the
study ML 17 032 (Kang et al.) a cost minimization analysis was performed (CMA).
Direct costs of the two alternative therapies were estimated based on the trial
results on actual dose and the number of administrations, and unit costs in Roma-
nian hospitals from payer perspective (National Health Insurance House). Adverse
event (AE) profiles were used to calculate costs of treating AEs. An expert panel
estimated typical treatment patterns and costs of treating major AEs. RESULTS: XP
arm patients received 5.2 cycles vs. 4.6 cycles in FP arm. The substitution of oral
capecitabine for infusional 5-FU reduced the number of hospital clinic visits by 17.6
(22.8 for FP versus 5.2 for XP). Drug costs were estimated to be ROL 5,230 greater in
the XP arm, but drug administration costs were ROL 5,904 lower, yielding a net cost
saving of ROL 674 per patient (1Euro4,2 ROL). Adverse event profiles were almost
similar: associated costs to treat AEs were less than ROL 270 per patient and were
lower in the XP arm by ROL 67. Total incremental cost was - ROL 741 in favor of XP
regimen. CONCLUSIONS: Oral capecitabine treatment is a cost-saving regimen for
AGC from Romanian public payer’s perspective.
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OBJECTIVES: Metastatic colorectal cancer (mCRC) accounts for a substantial eco-
nomic and clinical burden worldwide. The aim of the present study was to conduct
an economic evaluation in Greece comparing panitumumab with cetuximab in the
monotherapy treatment of patients with non-mutated (wild-type) KRAS, epider-
mal growth factor receptor (EGFR)-expressing mCRC. METHODS: Based on litera-
ture search, panitumumab and cetuximab are assumed to have similar efficacy,
hence a cost-minimization analysis was carried out from the third-payer-party
(Sickness Fund) and the National Health Service (NHS) perspective. A probabilistic
model was constructed to estimate the resource utilization and costs associated
with the management of patients receiving either therapy. Due to known differ-
ences in various settings regarding drug use, two type of analysis were undertaken:
one reporting “cost per mg” and another reporting “cost per vial”. Treatment cost
accounted for administration of second line chemotherapy, laboratory and bio-
chemical examinations and for hospitalization due to toxicity. Data on resource
utilization were collected from two oncology units in Greece and prices refer to
2011. Non parametric bootstrapping was employed to deal with uncertainty and to
estimate variability measures. RESULTS: From a third-payer-party perspective, it
was found that the mean 20-week total cost per patient for panitumumab and
cetuximab in the “per mg analysis” was €16,349 (95%CI: 16,036.7-16,637.8) and
€18,242 (95%CI: 17,902.4-18,597.9), respectively. The corresponding mean total
costs obtained in “per vial analysis” was €18,808 (95%CI: 18,437.7-19,161.7) and
€19,701 (95%CI: 19,358.6-20,053.1), respectively. From the NHS perspective, while
the mean total costs per patient were higher than for third party payers, versus
cetuximab, panitumumab was still associated with a 12.40% and 17.7% cost reduc-
tion in per-vial and per-mg analysis, respectively. CONCLUSIONS: In the Greek
NHS and Sickness Fund setting, panitimumab may represent a cost-saving option
compared with cetuximab in the management of patients with non-mutated (wild-
type) KRAS, epidermal growth factor receptor (EGFR)-expressing mCRC.
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CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS
FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III
COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD
COSTS IN THE NETHERLANDS
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OBJECTIVES: Recent publications have demonstrated equal efficacy of capecit-
abine and fluorouracil/leucovorin in combination with oxaliplatin in the adjuvant
treatment of stage III colon cancer. It is stated that CAPOX and FOLFOX can be used
interchangeably. METHODS: A cost-minimization analysis was performed using a
Markov model, a two-year time horizon and a hospital perspective. Assuming
equal efficacy of CAPOX and FOLFOX, transition probabilities were based on the
MOSAIC trial (Andre et al., 2004 and 2009). Dutch real-world population-based
treatment and follow-up cost were calculated using a representative sample of 102
patients treated with oxaliplatin for stage III colon cancer in 19 hospitals in the The
Netherlands. Resource use was collected from the first administration of adjuvant
chemotherapy until disease progression (or end of follow-up). Costs of drug acqui-
sition, drug administration, patient monitoring, and adverse events were consid-
ered and reported in euro 2009. RESULTS: In Dutch practice, the median time on
adjuvant treatment was 24 weeks for both CAPOX and FOLFOX, as recommended in
the guidelines. Mean total costs were € 19,373 for CAPOX and € 31,324 for FOLFOX,
resulting in a significant overall cost savings of € 11,951 for CAPOX compared with
FOLFOX. Main savings resulted from administration costs (€ 8,460), due to in-
creased hospital admissions in the FOLFOX treatment as the administration of
fluorouracil involves a 48-hour continuous infusion. Other savings were obtained
from acquisition costs (€ 2181) and costs of managing adverse events (€ 1427).
Monitoring costs were comparable in CAPOX and FOLFOX. Probabilistic sensitivity
analysis confirmed the robustness of the results. CONCLUSIONS: CAPOX is cost-
saving in comparison with FOLFOX for the adjuvant treatment of stage III colon
cancer in a real-world setting in the The Netherlands. Considering the high inci-
dence of colon cancer in the The Netherlands, substantial overall savings can be
realized by routine use of CAPOX in this indication.
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POTENTIAL BENEFITS OF INTRODUCING A COMPANION DIAGNOSTIC IN
ADVANCED NON-SMALL CELL LUNG CANCER
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OBJECTIVES: Gefitinib is a promising first-line treatment option in advanced non-
small cell lung cancer (NSCLC) patients with positive epidermal growth factor re-
ceptor tyrosine kinase (EGFR-TK) mutations. However, some patients with s`ensi-
tive´ EGFR-TK mutations and primary resistance do not respond to gefitinib
treatment. The objective of this early health technology assessment was to quan-
tify the potential health gain and cost consequences that would result with the
introduction of a companion diagnostic prior to first-line treatment of advanced
NSCLC patients with positive EGFR-TK mutations.METHODS:A Markov model was
designed to compare a companion diagnostic strategy (gefitinib or gemicitabine-
carboplatin) versus treating all patients with gefitinib (gefitinib for all). Model in-
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